Patents by Inventor Delf Schmidt

Delf Schmidt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8178359
    Abstract: A process for the quantitative optical analysis of fluorescently labeled biological cells involves contacting a cell layer on a transparent support at the bottom of a reaction vessel with a solution containing the fluorescent dye. This process can also be used for improving the sensitivity in the quantitative optical analysis of a luminescent biological cell layer. Analogously, these process principles can also be used in receptor studies for the masking of the interfering background radiation in the quantitative optical analysis of fluorescently or luminescently labelled reaction components. In this case, a receptor layer at the bottom of a reaction vessel is in contact with a solution in which a fluorescent or luminescent ligand is dissolved.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: May 15, 2012
    Assignee: Bayer Healthcare AG
    Inventors: Thoams Krahn, Wolfgang Paffhausen, Andreas Schade, Martin Bechem, Delf Schmidt
  • Patent number: 7615376
    Abstract: In a process for the quantitative optical analysis of fluorescently labelled biological cells 5, a cell layer on a transparent support at the bottom 2 of a reaction vessel 1 is in contact with a solution 3 containing the fluorescent dye 4. The sensitivity of analytical detection can be considerably improved if to the fluorescent dye 4 already present in addition a masking dye 9, which absorbs the excitation light 6 for the fluorescent dye 4 and/or its emission light 7, is added to the solution 3 and/or if a separating layer 10 permeable to the solution and absorbing and/or reflecting the excitation light 6 or the emission light 7 is applied to the cell layer at the bottom 2. This process can also be used for improving the sensitivity in the quantitative optical analysis of a luminescent biological cell layer. The separating layer 10 must in this case be composed such that it has a high power of reflection for the luminescent light 11.
    Type: Grant
    Filed: August 27, 2008
    Date of Patent: November 10, 2009
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Thomas Krahn, Wolfgang Paffhausen, Andreas Schade, Martin Bechem, Delf Schmidt
  • Publication number: 20080318270
    Abstract: In a process for the quantitative optical analysis of fluorescently labelled biological cells 5, a cell layer on a transparent support at the bottom 2 of a reaction vessel 1 is in contact with a solution 3 containing the fluorescent dye 4. The sensitivity of analytical detection can be considerably improved if to the fluorescent dye 4 already present in addition a masking dye 9, which absorbs the excitation light 6 for the fluorescent dye 4 and/or its emission light 7, is added to the solution 3 and/or if a separating layer 10 permeable to the solution and absorbing and/or reflecting the excitation light 6 or the emission light 7 is applied to the cell layer at the bottom 2. This process can also be used for improving the sensitivity in the quantitative optical analysis of a luminescent biological cell layer. The separating layer 10 must in this case be composed such that it has a high power of reflection for the luminescent light 11.
    Type: Application
    Filed: August 27, 2008
    Publication date: December 25, 2008
    Applicant: BAYER HEALTHCARE AG
    Inventors: Thomas Krahn, Wolfgang Paffhausen, Andreas Schade, Martin Bechem, Delf Schmidt
  • Patent number: 7320977
    Abstract: The invention relates to substituted 2-Phenyl-3(2H)-Pyridazinones, to a method for the production thereof, and to their use as medicaments for the prophylaxis and/or treatment of diseases in humans and/or animals.
    Type: Grant
    Filed: April 8, 2003
    Date of Patent: January 22, 2008
    Assignee: Bayer Healthcare AG
    Inventors: Rudolf Schohe-Loop, Elmar Burchardt, Christiane Faeste, Claudia Hirth-Dietrich, Jörg Keldenich, Andreas Knorr, Thomas Lampe, Paul Naab, Delf Schmidt, Gunter Schmidt
  • Publication number: 20070142420
    Abstract: Hetero-tetrahydroquinolines can be prepared either by condensing correspondingly substituted hetero-tetrahydroquinoline aldehydes with the desired substituent or by reducing the corresponding keto-substituted hetero-tetrahydroquinolines, followed by introduction of the desired substituent by customary methods. The hetero-tetrahydroquinolines are suitable for use as active compounds in medicaments, in particular in medicaments for treating artheriosclerosis and dyslipidaemias.
    Type: Application
    Filed: February 22, 2007
    Publication date: June 21, 2007
    Applicant: BAYER AKTIENGESELLSCHAFT
    Inventors: JURGEN STOLTEFUSS, MICHAEL LOGERS, GUNTER SCHMIDT, ARNDT BRANDES, CARSTEN SCHMECK, KLAUS BREMM, HILMAR BISCHOFF, DELF SCHMIDT
  • Patent number: 7192971
    Abstract: Hetero-tetrahydroquinolines can be prepared either by condensing correspondingly substituted hetero-tetrahydroquinoline aldehydes with the desired substituent or by reducing the corresponding keto-substituted hetero-tetrahydroquinolines, followed by introduction of the desired substituent by customary methods. The hetero-tetrahydroquinolines are suitable for use as active compounds in medicaments, in particular in medicaments for treating artheriosclerosis and dyslipidaemias.
    Type: Grant
    Filed: October 25, 2005
    Date of Patent: March 20, 2007
    Assignee: Bayer Aktiengesellschaft
    Inventors: Jürgen Stoltefuss, Michael Lörges, Gunter Schmidt, Arndt Brandes, Carsten Schmeck, Klaus-Dieter Bremm, Hilmar Bischoff, Delf Schmidt
  • Patent number: 7138280
    Abstract: In a process for the quantitative optical analysis of biological cells labelled with a fluorescent dye, the sensitivity of analytical detection can be considerably improved if a masking dye, which absorbs the excitation light for the fluorescent dye and/or its emission light is added to the solution surrounding the biological cells and/or if a separating layer permeable to the solution and absorbing and/or reflecting the excitation light or the emission light is applied to a layer of the biological cells at the bottom of a reaction vessel. This process can also be used for improving the sensitivity in the quantitative optical analysis of a luminescent biological cell layer. Analogously, these process principles can also be used in receptor studies for the masking of the interfering background radiation in the quantitative optical analysis of fluorescently or luminescently labelled reaction components.
    Type: Grant
    Filed: October 3, 2002
    Date of Patent: November 21, 2006
    Assignee: Bayer Healthcare AG
    Inventors: Thomas Krahn, Wolfgang Paffhausen, Andreas Schade, Martin Bechem, Delf Schmidt
  • Patent number: 7094911
    Abstract: The present invention relates to biphenyl and biphenyl-analogous compounds, their preparation and use as pharmaceutical compositions, as integrin antagonists and in particular for the production of pharmaceutical compositions for the treatment and prophylaxis of cancer, arteriosclerosis, restenosis, osteolytic disorders such as osteoporosis and ophthalmic diseases. The compounds according to the invention have the formula (1) wherein R1, R2, U, V, A, B, W, R3, C and R4 have the meaning as defined in the claims.
    Type: Grant
    Filed: October 31, 2002
    Date of Patent: August 22, 2006
    Assignee: Bayer Aktiengesellschaft
    Inventors: Markus Albers, Klaus Urbahns, Andrea Vaupel, Michael Härter, Delf Schmidt, Beatrix Stelte-Ludwig, Christoph Gerdes, Elke Stahl, Jörg Keldenich, Ulf Brueggemeier, Klemens Lustig
  • Patent number: 7063952
    Abstract: In a process for the quantitative optical analysis of fluorescently labelled biological cells 5, a cell layer on a transparent support at the bottom 2 of a reaction vessel 1 is in contact with a solution 3 containing the fluorescent dye 4. The sensitivity of analytical detection can be considerably improved if to the fluorescent dye 4 already present in addition a masking dye 9, which absorbs the excitation light 6 for the fluorescent dye 4 and/or its emission light 7, is added to the solution 3 and/or if a separating layer 10 permeable to the solution and absorbing and/or reflecting the excitation light 6 or the emission light 7 is applied to the cell layer at the bottom 2. This process can also be used for improving the sensitivity in the quantitative optical analysis of a luminescent biological cell layer. The separating layer 10 must in this case be composed such that it has a high power of reflection for the luminescent light 11.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: June 20, 2006
    Assignee: Bayer Healthcare AG
    Inventors: Thoams Krahn, Wolfgang Paffhausen, Andreas Schade, Martin Bechem, Delf Schmidt
  • Publication number: 20060069112
    Abstract: Hetero-tetrahydroquinolines can be prepared either by condensing correspondingly substituted hetero-tetrahydroquinoline aldehydes with the desired substituent or by reducing the corresponding keto-substituted hetero-tetrahydroquinolines, followed by introduction of the desired substituent by customary methods. The hetero-tetrahydroquinolines are suitable for use as active compounds in medicaments, in particular in medicaments for treating artheriosclerosis and dyslipidaemias.
    Type: Application
    Filed: October 25, 2005
    Publication date: March 30, 2006
    Applicant: Bayer Aktiengesellschaft
    Inventors: Jürgen Stoltefuß, Michael Lörges, Gunter Schmidt, Arndt Brandes, Carsten Schmeck, Klaus-Dieter Bremm, Hilmar Bischoff, Delf Schmidt
  • Patent number: 7015246
    Abstract: The invention relates to novel benzofuran derivatives, to processes for preparing them and to their uses in medicaments.
    Type: Grant
    Filed: October 10, 2002
    Date of Patent: March 21, 2006
    Assignee: Bayer Aktiengesellschaft
    Inventors: Carsten Schmeck, Ulrich Müller, Gunter Schmidt, Josef Pernerstorfer, Hilmar Bischoff, Axel Kretschmer, Verena Vöhringer, Christiane Faeste, Helmut Haning, Markus Hauswald, Delf Schmidt, Martin Zoche, Heiner Apeler, Willi Jonghaus, Peter Reinemer
  • Publication number: 20060004015
    Abstract: The invention relates to substituted 2-phenyl-3(2h)-pyridazinones, to a method for the production thereof, and to their use as medicaments used in the prophylaxis and/or treatment of diseases in humans and/or animals.
    Type: Application
    Filed: April 8, 2003
    Publication date: January 5, 2006
    Inventors: Rudolf Schohe-Loop, Elmar Burchardt, Christiane Faeste, Claudia Hirth-Dietrich, Jorg Keldenich, Andreas Knorr, Thomas Lampe, Paul Naab, Delf Schmidt
  • Patent number: 6958346
    Abstract: Hetero-tetrahydroquinolines can be prepared either by condensing correspondingly substituted hetero-tetrahydroquinoline aldehydes with the desired substituent or by reducing the corresponding keto-substituted hetero-tetrahydroquinolines, followed by introduction of the desired substituent by customary methods. The hetero-tetrahydroquinolines are suitable for use as active compounds in medicaments, in particular in medicaments for treating artheriosclerosis and dyslipidaemias.
    Type: Grant
    Filed: October 31, 2001
    Date of Patent: October 25, 2005
    Assignee: Bayer Aktiengesellschaft
    Inventors: Jürgen Stoltefuss, Michael Lögers, Gunter Schmidt, Arndt Brandes, Carsten Schmeck, Klaus-Dieter Bremm, Hilmar Bischoff, Delf Schmidt
  • Patent number: 6897317
    Abstract: The tetrahydroquinolines can be prepared by condensing appropriately substituted tetrahydroquinoline aldehydes with suitable substances and subsequently varying the substituents present by customary methods. The tetrahydroquinolines are suitable as active compounds in medicaments, in particular in medicaments for the treatment of arteriosclerosis and dyslipidaemias.
    Type: Grant
    Filed: March 31, 2003
    Date of Patent: May 24, 2005
    Assignee: Bayer Aktiengesellschaft
    Inventors: Gunter Schmidt, Jürgen Stoltefuss, Michael Lögers, Arndt Brandes, Carsten Schmeck, Klaus-Dieter Bremm, Hilmar Bischoff, Delf Schmidt
  • Publication number: 20050043341
    Abstract: The application relates to substituted tetrahydroquinoline derivatives, processes for their preparation and their use in medicaments.
    Type: Application
    Filed: September 18, 2002
    Publication date: February 24, 2005
    Inventors: Heike Gielen, Siegfried Goldmann, Jorg Keldenich, Holger Paulsen, Carsten Schmeck, Stephan Siegel, Hilmar Bischoff, Martin Raabe, Delf Schmidt, Christiane Faeste
  • Publication number: 20040220415
    Abstract: The invention relates to novel benzofuran derivatives, to processes for preparing them and to their uses in medicaments.
    Type: Application
    Filed: April 12, 2004
    Publication date: November 4, 2004
    Inventors: Carsten Schmeck, Ulrich Muller, Gunter Schmidt, Josef Pernerstorfer, Hilmar Bischoff, Axel Kretschmer, Verena Vohringer, Christiane Faeste, Helmut Haning, Markus Hauswald, Delf Schmidt, Martin Zoche, Heiner Apeler, Willi Jonghaus, Peter Reinemer
  • Publication number: 20040030132
    Abstract: The present invention relates to biphenyl and biphenyl-analogous compounds, their preparation and use as pharmaceutical compositions, as integrin antagonists and in particular for the production of pharmaceutical compositions for the treatment and prophylaxis of cancer, arteriosclerosis, restenosis, osteolytic disorders such as osteoporosis and ophthalmic diseases.
    Type: Application
    Filed: October 31, 2002
    Publication date: February 12, 2004
    Inventors: Markus Albers, Klaus Urbahns, Andrea Vaupel, Michael Harter, Delf Schmidt, Beatrix Stelte-Ludwig, Christoph Gerdes, Elke Stahl, Jorg Keldenich, Ulf Brueggemeier, Klemens Lustig
  • Patent number: 6677360
    Abstract: The present invention relates to biphenyl and biphenyl-analogous compounds, their preparation and use as pharmaceutical compositions, as integrin antagonists and in particular for the production of pharmaceutical compositions for the treatment and prophylaxis of cancer, arteriosclerosis, restenosis, osteolytic disorders such as osteoporosis and ophthalmic diseases. The compounds according to the invention have the formula (1) wherein R1, R2, U, V, A, B, W, R3, C and R4 have the meaning as defined in the claims.
    Type: Grant
    Filed: April 6, 2001
    Date of Patent: January 13, 2004
    Assignee: Bayer Aktiengesellschaft
    Inventors: Markus Albers, Klaus Urbahns, Andrea Vaupel, Michael Härter, Delf Schmidt, Beatrix Stelte-Ludwig, Christoph Gerdes, Elke Stahl, Jörg Keldenich, Ulf Brueggemeier, Klemens Lustig
  • Publication number: 20030232990
    Abstract: The tetrahydroquinolines can be prepared by condensing appropriately substituted tetrahydroquinoline aldehydes with suitable substances and subsequently varying the substituents present by customary methods. The tetrahydroquinolines are suitable as active compounds in medicaments, in particular in medicaments for the treatment of arteriosclerosis and dyslipidaemias.
    Type: Application
    Filed: March 31, 2003
    Publication date: December 18, 2003
    Applicant: Bayer Aktiengesellschaft
    Inventors: Gunter Schmidt, Jurgen Stoltefuss, Michael Logers, Arndt Brandes, Carsten Schmeck, Klaus-Dieter Bremm, Hilmar Bischoff, Delf Schmidt
  • Patent number: 6589972
    Abstract: The present invention relates to compounds of the general formula (1) wherein R4 is —SO2R4′, —COOR4″, —COR4′, —CONR4′2 or —CSNR4′2; R4′ is hydrogen, a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted aryl residue or a saturated or unsaturated, optionally substituted heterocyclic residue; R4″ is a substituted or unsubstituted alkyl or cycloalkyl residue, a substituted or unsubstituted aryl residue or a saturated or unsaturated, optionally substituted heterocyclic residue; L is a sulphonamide, amide, ether, ester, keto, urea, thioether, sulphoxide or sulphone unit optionally extended by one or two methylene groups; and X is N, O or S; and their physiologically acceptable salts and stereoisomers.
    Type: Grant
    Filed: May 30, 2001
    Date of Patent: July 8, 2003
    Assignee: Bayer Aktiengesellschaft
    Inventors: Andreas Schoop, Gerhard Mueller, Ulf Brueggemeier, Delf Schmidt, Beatrix Stelte-Ludwig, Joerg Keldenich